Anthrax Therapeutic Development and Pipeline Review H1 2015 Research Report

DALLAS, March 23, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Anthrax - Pipeline Review, H1 2015" report to its store. The report provides an overview of the Anthrax's therapeutic pipeline.

The report "Anthrax - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anthrax. Anthrax is an uncommon but serious illness caused by a spore-forming bacterium, Bacillus anthracis. Anthrax mainly affects livestock and wild game. Humans can become infected through direct or indirect contact with sick animals. It can cause three forms of disease in people. They are Cutaneous, Inhalation and Gastrointestinal. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, bloody diarrhea, sore throat and difficulty swallowing. The report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

The report also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Companies discussed in this report include Aduro BioTech, Inc., Aradigm Corporation, Bavarian Nordic A/S, Bristol-Myers Squibb Company, ContraFect Corporation, Dynavax Technologies Corporation, Elusys Therapeutics, Inc., Emergent BioSolutions Inc., Evolva SA, Green Cross Corporation, Grifols, S.A., Hawaii Biotech, Inc., iBio, Inc., Immunovaccine, Inc., Innovative Biologics, Inc., Microbiotix, Inc., NanoBio Corporation, Navigen Pharmaceuticals, Inc., Oragenics, Inc., PaxVax, Pfenex Inc., Planet Biotechnology Inc., Protein Potential, LLC, ProThera Biologics, LLC., PsiOxus Therapeutics, Ltd., Revivicor, Inc., SelectX Pharmaceuticals, Inc., Soligenix, Inc., Summit Corporation plc, Syntiron LLC, Tetraphase Pharmaceuticals Inc., The Medicines Company, Vaxin, Inc.

Drug Profiles in this report include anthrax + plague vaccine, anthrax vaccine, anthrax vaccine next generation, ARD-3100, AV-7909, CF-307, CF-308, ciprofloxacin hydrochloride, DPX-Anthrax, DV-230, EV-021, GC-1109, GREANX, Human Antibody Based Vaccines, KKL-35, MDX-1303, Monoclonal Antibody for Respiratory Anthrax, Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax, MU-1140, MVA-BN Anthrax, NP-015, obiltoxaximab, oritavancin diphosphate, PBI-220, PreviThrax, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, Px-563L, RiVax + VeloThrax, Second Generation Px-563L, SGX-204, Slit2N, Small Molecule to Inhibit Anthrax Toxin for Anthrax, Small Molecules for Bacterial Infections, Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis, Small Molecules to Inhibit MMP, SMT-15000, TP-271. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310136 . (This is a premium report priced at US$2000 for a single user License.)

The scope of the report ranges from global therapeutic landscape of Anthrax to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Explore more reports on Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

More reports on Therapeutics Market:

Gastric Ulcers - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Gastric Ulcers. Companies discussed in this report include Astellas Pharma Inc., ChoDang Pharm Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Priaxon AG, Sihuan Pharmaceutical Holdings Group Ltd. Complete report available at http://www.rnrmarketresearch.com/gastric-ulcers-pipeline-review-h1-2015-market-report.html .

Gastroparesis - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Gastroparesis. The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include GlaxoSmithKline plc, RaQualia Pharma Inc. Complete report available at http://www.rnrmarketresearch.com/gastroparesis-pipeline-review-h1-2015-market-report.html .

Fecal Incontinence - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Fecal Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report Celogos, Cook MyoSite Incorporated, Innovacell Biotechnologie AG, Norgine B.V., RDD Pharma Ltd., S.L.A. Pharma AG. Complete report available at http://www.rnrmarketresearch.com/fecal-incontinence-pipeline-review-h1-2015-market-report.html .

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development are Almirall, S.A., Eisai Co., Ltd., Ironwood Pharmaceuticals, Inc., RaQualia Pharma Inc., Rottapharm SpA, Zeria Pharmaceutical Co Ltd. Complete report available at http://www.rnrmarketresearch.com/functional-non-ulcer-dyspepsia-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com